Successful treatment of refractory gastroesophageal reflux-induced chronic cough with vonoprazan: a report of three cases.

IF 1.8

The American journal of the medical sciences Pub Date : 2025-08-22 DOI:10.1016/j.amjms.2025.08.019

Tong-Yang-Zi Zhang, Lu-Di Fei, Ji-Guang Wu, Yi-Qing Zhu, Wan-Zhen Li, Sheng-Yuan Wang, Xiang-Huai Xu, Li Yu

{"title":"Successful treatment of refractory gastroesophageal reflux-induced chronic cough with vonoprazan: a report of three cases.","authors":"Tong-Yang-Zi Zhang, Lu-Di Fei, Ji-Guang Wu, Yi-Qing Zhu, Wan-Zhen Li, Sheng-Yuan Wang, Xiang-Huai Xu, Li Yu","doi":"10.1016/j.amjms.2025.08.019","DOIUrl":null,"url":null,"abstract":"Background: Gastroesophageal reflux-induced chronic cough (GERC) is a common cause of chronic cough, with an increasing incidence over the years. Proton-pump inhibitors (PPIs) are the standard treatment for GERC, but some patients exhibit poor response to PPIs. Vonoprazan, a potassium-competitive acid blocker (P-CAB), offers enhanced acid inhibition compared to PPIs and has shown effectiveness in treating GERC. However, its efficacy in refractory GERC cases has not been widely reported.Methods: This report examines three cases of refractory GERC in which patients did not experience significant symptom relief after 8 weeks of PPI treatment. The treatment was switched to vonoprazan to evaluate its effectiveness in alleviating chronic cough symptoms.Results: All three patients demonstrated complete relief from chronic cough after the transition to vonoprazan, indicating its potential effectiveness in cases where PPIs failed to provide sufficient symptom control.Conclusions: Vonoprazan is a promising clinical application in the treatment of refractory GERC.","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The American journal of the medical sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.amjms.2025.08.019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Gastroesophageal reflux-induced chronic cough (GERC) is a common cause of chronic cough, with an increasing incidence over the years. Proton-pump inhibitors (PPIs) are the standard treatment for GERC, but some patients exhibit poor response to PPIs. Vonoprazan, a potassium-competitive acid blocker (P-CAB), offers enhanced acid inhibition compared to PPIs and has shown effectiveness in treating GERC. However, its efficacy in refractory GERC cases has not been widely reported.

Methods: This report examines three cases of refractory GERC in which patients did not experience significant symptom relief after 8 weeks of PPI treatment. The treatment was switched to vonoprazan to evaluate its effectiveness in alleviating chronic cough symptoms.

Results: All three patients demonstrated complete relief from chronic cough after the transition to vonoprazan, indicating its potential effectiveness in cases where PPIs failed to provide sufficient symptom control.

Conclusions: Vonoprazan is a promising clinical application in the treatment of refractory GERC.

查看原文本刊更多论文

伏诺哌赞成功治疗难治性胃食管反流性慢性咳嗽3例报告

背景：胃食管反流性慢性咳嗽（GERC）是慢性咳嗽的常见原因，近年来发病率不断上升。质子泵抑制剂（PPIs）是GERC的标准治疗方法，但一些患者对PPIs的反应较差。Vonoprazan是一种钾竞争性酸阻滞剂（P-CAB），与PPIs相比，它具有更强的酸抑制作用，并已显示出治疗GERC的有效性。然而，其在难治性GERC病例中的疗效尚未得到广泛报道。方法：本报告研究了3例难治性GERC，患者在接受PPI治疗8周后症状没有明显缓解。治疗转为伏诺哌赞，以评估其缓解慢性咳嗽症状的有效性。结果：所有3例患者在改用vonoprazan后均表现出慢性咳嗽的完全缓解，这表明在PPIs无法提供足够症状控制的情况下，vonoprazan可能有效。结论：Vonoprazan治疗难治性GERC具有良好的临床应用前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

The American journal of the medical sciences

自引率

0.00%

发文量